The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...

Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...

Genentech is planning a massive overhaul of its 207-acre South San Francisco campus that could cost between $3B and $5B by the time the multiphase project is complete, according to the San Francisco ...

Here's what lies ahead Drug giant promises $50 billion U.S. investment Drug giant promises $50 billion U.S. investment Bay ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from its CD20xCD3 T-cell engaging bispecific antibo ...

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus.

The drug was developed at Genentech Dr. Mark Sliwkowski, who has been instrumental in all HER2-targeted medicines. Dr. Kip Benyunes, a clinician, also worked closely on the development of Pertuzumab.

Genentech, founded in 1976, has worked closely with Roche for two decades. Roche acquired a 60 percent interest in Genentech in 1990. It bought out the rest of the shares nine years later but then ...

Genentech’s overarching campaign is part of the company’s embrace of diversity, equity and inclusion efforts, including diversifying its clinical trials and its supplier base, Dunn said.

Genentech, the maker of cancer drug blockbusters Rituxan, Herceptin and Avastin, said Monday it would form a committee of independent directors to assess the offer.

For the Bay Area, the impact of Genentech's sale goes far beyond a change of nameplates on a big local company. Genentech was the region's home-grown luminary, with a leading role in the ...